QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing
March 4, 2025
QIAGEN N.V. announced that it has filed a complaint against bioMérieux S.A. for patent infringement to protect the scientific advancements behind its proprietary QuantiFERON technology.
The complaint, filed in the Local Division of the Court of First Instance of the Unified Patent Court (UPC) in Duesseldorf, Germany, concerns European Patent EP 2 276 883 B2. This patent, which is one of many held by QIAGEN protecting the QuantiFERON technology, covers important innovations in QuantiFERON-TB Gold Plus that is used worldwide for TB detection.
